Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

FDA approves targeted therapy for tumors with KRAS mutations

Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy.

29 May 2021

FDA approves Rybrevant for treating subset of non-small cell lung cancer

Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

21 May 2021

New approach combines molecular and medical imaging data to diagnose cancer type

Despite our remarkable advances in medicine and healthcare, the cure to cancer continues to elude us. On the bright side, we have made considerable progress in detecting several cancers in earlier stages, allowing doctors to provide treatments that increase long-term survival.

11 May 2021

Study identifies novel combination therapy to help patients with advanced lung cancer

A new study by researchers at the UCLA Jonsson Comprehensive Cancer Center has identified a novel combination therapy to potentially help overcome resistance to immunotherapy in people diagnosed with advanced lung cancer.

5 May 2021

Preoperative sarcopenia and exercise intolerance predict outcomes following lung cancer surgery

Lung cancer is a major global cause of mortality, reportedly accounting for 1.7 million deaths each year. The most common form of lung cancer is non-small-cell lung cancer (NSCLC), and early-stage NSCLCs can often be surgically resected.

26 Apr 2021

Contralateral esophagus sparing technique can prevent complication in lung cancer patients

For many patients with localized lung cancer (non-small-cell lung carcinoma and small cell lung carcinoma), high-dose radiation with concurrent chemotherapy is a potential cure. Yet this treatment can cause severe, acute inflammation of the esophagus (esophagitis) in about one in five patients, requiring hospitalization and placement of a feeding tube.

23 Apr 2021

Anti-diabetic drug phenformin may prompt stronger cancer-fighting activities

The anti-diabetic drug phenformin may prompt stronger cancer-fighting activities than its sister compound metformin, a finding that could have major implications for current and future clinical trials investigating both agents for their anti-cancer potential, according to researchers at Massachusetts General Hospital (MGH).

15 Apr 2021

New genetic markers may lead to personalized treatments for lung cancer

Investigators at Wake Forest School of Medicine, part of Wake Forest Baptist Health, have identified a set of new genetic markers that could potentially lead to new personalized treatments for lung cancer.

15 Apr 2021

Aneuploidy testing can be key in determining optimal treatment for lung cancer patients

Patients with non-small cell lung cancer (NSCLC) whose cancer cells have low levels of aneuploidy - an abnormal number of chromosomes - tend to respond better to immune checkpoint inhibitor drugs than patients with higher levels, Dana-Farber Cancer Institute researchers will report at the virtual AACR Annual Meeting 2021.

12 Apr 2021

Phase 3 clinical trial tests new treatment for brain metastases from small-cell lung cancer

A new phase 3 randomized clinical trial overseen by CU Cancer Center member Chad Rusthoven, MD, and Vinai Gondi, MD, from Northwestern University, is testing whether a new treatment approach could result in improved outcomes for patients with small cell lung cancer (SCLC) that has spread to the brain.

8 Apr 2021

Researchers discover two new ways to treat small cell lung tumors

Using samples of small cell lung tumors, a research team led by biologist Dr Silvia von Karstedt has discovered two new ways to induce tumor cell death. One of two subsets of tumor cells can be targeted by activating ferroptosis: iron-dependent cell death caused by oxidative stress

7 Apr 2021

High expression of cell death genes may increase risk of early death from lung cancer

Patients with a high number of genes most associated with pathways that lead to cell death in lung cancer are at increased risk of dying early from their disease, researchers report.

5 Apr 2021

Evidence-based clinical practice guideline aims to optimize PD-L1 lung tumor testing

The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immunooncology therapy.

1 Apr 2021

NCCN Annual Conference discusses new ways to improve cancer care

New recommendations to advance racial equity, ways to mitigate the impacts of the COVID-19 pandemic on cancer care, and ongoing strategies for preventing and controlling HPV-associated cancers led the conversation at the National Comprehensive Cancer Network® (NCCN®) 2021 Virtual Annual Conference March 18-20.

25 Mar 2021

Study finds significant variation in biomarker test utilization and treatment for non–small-cell lung cancer

Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however its use has complicated the diagnosis of non-small-cell lung cancer (NSCLC).

15 Mar 2021

Novel method can improve the detection of circulating tumor cells

Non-Small Cell Lung Cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80 percent of all lung cancer cases.

10 Mar 2021

Newly identified biomarker could predict response to immune checkpoint inhibitors

A team of Roswell Park Comprehensive Cancer Center researchers has identified a new biomarker that could predict response to immune checkpoint inhibitors (ICI) shortly after patients with non-small cell lung cancer (NSCLC) initiate therapy.

3 Mar 2021

COVID-19 and lung cancer have a common pathway, say researchers

A new preprint on the bioRxiv* server describes the common features COVID-19 shares with lung cancer.

19 Feb 2021

Combination therapy produces clinical benefit for early stage non-small cell lung cancer

The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.

18 Feb 2021

FDA approves drug to reduce frequency of chemotherapy-induced bone marrow suppression

Today, the U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer.

13 Feb 2021